Shijun Li

Signal Transduction and Targeted Therapy · 2022

A researcher in the Science corpus: 1 paper; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.

Whom Shijun Li trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. R. Medzhitov

Papers from Shijun Li's perspective

Ordered by how strongly the researchers Shijun Li trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index (Nature Biotechnology)
  2. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. (Cancer Research)
  3. Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates (Nature Biotechnology)
  4. Paul Ehrlich's magic bullet concept: 100 years of progress (Nature Reviews. Cancer)
  5. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. (Clinical Cancer Research)
  6. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer (New England Journal of Medicine)
  7. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. (The Lancet)
  8. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. (Journal of Clinical Oncology)
  9. The Addition of Gemtuzumab Ozogamicin to Induction Chemotherapy in Acute Myeloid Leukaemia : An IndividualPatient Data Meta-analysis of Randomised Trials in Adults (The Lancet Oncology)
  10. Competition for FcRn-mediated transport gives rise to short half-life of human IgG3 and offers therapeutic potential

Their papers